ライフサイエンスコーパス: overdose

1 ia) and their adverse effects (addiction and overdose).

2 5 mg Fe/g liver phantom iron overload (100X overdose).

3 ose dependent and impaired after severe APAP overdose.

4 d grafts from donors who died of anoxic drug overdose.

5 he standard of care drug for treating opioid overdose.

6 terns preceding opioid use disorder (OUD) or overdose.

7 sociated with death from prescription opioid overdose.

8 k for hepatotoxicity following acetaminophen overdose.

9 macrophages into necrotic lesions after APAP overdose.

10 r progression of injury and death after APAP overdose.

11 ce from cocaine-seeking behavior and cocaine overdose.

12 ting acute hepatotoxicity attributed to APAP overdose.

13 e currently used for the treatment of opioid overdose.

14 for treating METH use disorder or reversing overdose.

15 regulator of macrophage function after APAP overdose.

16 h heroin, and can result in lethality during overdose.

17 pposed progression of liver injury upon APAP overdose.

18 and QTc intervals, as seen with azithromycin overdose.

19 her risk of subsequent opioid dependency and overdose.

20 in the liver of patients with acetaminophen overdose.

21 ffective medication for treatment of cocaine overdose.

22 e is associated with lower risk for repeated overdose.

23 ous risks, including opioid use disorder and overdose.

24 e treated for a nonfatal prescription-opioid overdose.

25 d treatment for nonfatal prescription-opioid overdose.

26 of patients (n = 212) had a repeated opioid overdose.

27 enerally safe they are potentially lethal in overdose.

28 ays before to up to 730 days after the index overdose.

29 nue to receive prescription opioids after an overdose.

30 mon drugs associated with unintentional drug overdose.

31 s were dispensed to 91% of patients after an overdose.

32 mortality risk, especially for drug-related overdose.

33 ostic biomarker of patient outcome post-APAP overdose.

34 ating miRNome in patients with acetaminophen overdose.

35 may be a powerful approach to combat opioid overdose.

36 has led to major problems with addiction and overdose.

37 he KF may be an effective approach to combat overdose.

38 -home naloxone programs aim to prevent fatal overdose.

39 tion of proinflammatory cytokines after APAP overdose.

40 for liver repair after acetaminophen (APAP) overdose.

41 low risk of liver injury from acetaminophen overdose.

42 00 people (105 800-113 600) died from opioid overdose.

43 tributor to the rising mortality from opioid overdoses.

44 ave been reported from single-agent hypnotic overdoses.

45 rder, and over 100 die every day from opioid overdoses.

46 ts experienced one or more medically treated overdoses.

47 ication of suicides as car crashes or opioid overdoses.

48 ritically ill to both piperacillin under and overdosing.

49 blunts hypoglycaemia in dogs in response to overdosing.

50 ommon self-harm mechanism was an intentional overdose (115 [72.8%]).

51 -of-hospital deaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), th

52 ving high dosages of opioids after the index overdose, 15% (CI, 10% to 21%) for those receiving moder

53 ed patients (9.4%) were underdosed, 197 were overdosed (3.4%), and 5,000 were dosed according to U.S.

54 Of 227,038 adults with incident OUD or overdose, 33.1% were aged 18 to 30 years, 52.9% were mal

55 Seizures and overdoses accounted for 25 of the 29 related SAEs.

56 ratio, 2.85; 95% CI, 1.54-5.47), and opioid overdose (adjusted hazard ratio, 5.12; 95% CI, 1.63-19.6

57 high rates of relapse and increased risk of overdose after leaving treatment.

58 ing across all racial groups, caused by drug overdoses, alcohol abuse, suicides, and a diverse list o

59 s in potentially hazardous use of opioids or overdose among disabled Medicare beneficiaries, a popula

60 preventing HIV, hepatitis C virus (HCV), and overdose among PWID, our modeling suggests that OAT scal

61 This risk factor for fatal overdose among veterans underscores the importance of ca

62 ide, alcohol-related liver disease, and drug overdose among young adults has become a critical public

63 They found a decrease in numbers of opioid-overdose and car-crash deaths compared with what would h

64 ough buprenorphine treatment reduces risk of overdose and death in opioid use disorder, most patients

65 The most common cause of opioid overdose and death is opioid-induced respiratory depress

66 We excluded studies of deliberate overdose and depression in non-ICU settings.

67 trate liver as early as 8-12 hours post-APAP overdose and form dense cellular clusters around necroti

68 ole of GSK3 in liver regeneration after APAP overdose and identified GSK3 as a potential therapeutic

69 o adequately measure and monitor the risk of overdose and inform health policies.

70 tional states can lead to involuntary opioid overdose and many neuropsychiatric comorbidities.

71 e antagonist that can reverse the effects of overdose and minimizing the delay in administering the a

72 of distinguishing between episodes of opioid overdose and nerve agent poisoning.

73 able treatment modality for synthetic opioid overdose and possibly opioid use disorder.

74 f organs from donors who died of anoxic drug overdose and recipients of organs from donors who died o

75 in the bictegravir group (recreational drug overdose and suicide, neither of which was treatment rel

76 pants in the BA group (two [1%] patients who overdosed and one [1%] who self-harmed) and eight (4%) p

77 articipants in the CBT group (seven [4%] who overdosed and one [1%] who self-harmed).

78 rugs that have been associated with numerous overdoses and fatalities.

79 past decade, psychostimulant-related lethal overdoses and hospitalizations have skyrocketed 127 and

80 s is desirable to direct the care pathway of overdoses and provide information for informed consent.

81 cost-effective technologies to track patient overdosing and to monitor ambient water sources and wast

82 nal indication for dose reduction (potential overdosing) and use of a reduced dose when the renal ind

83 ed public health issues of opioid diversion, overdose, and addiction.

84 reased risks, including opioid use disorder, overdose, and death, with dose-dependent effects.

85 opioids results in analgesic tolerance, drug overdose, and death.

86 tened risk for long-term opioid use, misuse, overdose, and death.

87 a risk of adverse effects such as addiction, overdose, and death.

88 here is currently an epidemic of opioid use, overdose, and dependence in the United States.

89 n Scotland), were diagnosed with paracetamol overdose, and gave written informed consent.

90 ignificantly older, less likely to have APAP overdose, and had a lower overall 3-week survival compar

91 -hospital settings on mortality, reversal of overdose, and harms, and 2) the need for transport to a

92 rtality, reversal of overdose, recurrence of overdose, and harms.

93 an opioid antagonist used to reverse opioid overdose, and take-home naloxone programs aim to prevent

94 ve indicated potential adverse effects of FA overdoses, and FA protection during processing and stora

95 the closed-loop release mechanism to revive overdosed animals.

96 Acetaminophen (APAP) overdose (APAPo) is predominant in the NIH Pediatric Acu

97 Opioid addiction and overdose are at record levels in the United States.

98 for acute emergencies resulting from cocaine overdose are lacking.

99 disorders, but treatment patterns after the overdose are unknown.

100 Acetaminophen (APAP) overdoses are of major clinical concern.

101 patients at risk of DILI after acetaminophen overdose (area under ROC curve 0.98 (95% CI; 0.96-1), P

102 mes, including misuse, abuse, addiction, and overdose, arising from use of TIRFs.

103 of an enzyme-based novel therapy for cocaine overdose as a successful example in comparison with the

104 ocytes and attenuated liver injury post-APAP overdose at early time points.

105 ncluded training for the treatment of opioid overdose; basic life support, including automated extern

106 2 expression occurs in mice on acetaminophen overdose because of suppression of its key transactivato

107 sers at risk of opioid use disorder (OUD) or overdose between 2011 and 2014.

108 Naloxone is effective for reversing opioid overdose, but optimal strategies for out-of-hospital use

109 Based on 16 studies, the pooled overdose CMRs were 0.24 (0.20-0.28) while receiving MAT,

110 Publicly available information about opiate overdoses, combined with data on spatiotemporal risk fac

111 accumulation and higher mortality after APAP overdose compared to ASMase(+/+) littermates.

112 ith clinical use but overlap with postmortem overdose concentrations.

113 oses were classified as either underdosed or overdosed, consistent with Food and Drug Administration

114 ght of the accelerating and rapidly evolving overdose crisis in the United States (US), new strategie

115 s is in the midst of an opioid addiction and overdose crisis precipitated and exacerbated by use of p

116 s been touted as a solution to the US opioid overdose crisis since Bachhuber et al. found that from 1

117 h aimed at finding treatments for the opioid overdose crisis.

118 The all-cause and overdose crude mortality rates (CMRs) and relative risks

119 opioid epidemic, utilization of anoxic drug overdose DCD donor grafts does not increase the risk of

120 sk of all-cause death (2.33 [2.02-2.67]) and overdose death (3.09 [2.37-4.01]).

121 vailability and is the leading cause of drug overdose death in the U.S.

122 Mortality assessed by drug overdose death rates involving prescription opioids incr

123 ing medical cannabis laws will reduce opioid overdose death should be met with skepticism.

124 Drug overdose deaths (largely attributable to opioid misuse)

125 ) and 3.3% (95% CI 3.1%-3.4%), respectively, overdose deaths among PWID by 10.0% (95% CI 9.8%-10.8%),

126 the past 20 years, leading to high rates of overdose deaths and a dramatic increase in the number of

127 ion and its associated costs, and also avert overdose deaths and improve quality of life for PWID, PW

128 d the association of those reforms with drug overdose deaths and other injury fatalities.

129 The rising number of drug overdose deaths and the changing legal status of marijua

130 mine ongoing public health efforts to reduce overdose deaths and the spread of infectious disease in

131 h OUD globally in 2016, with >100,000 opioid overdose deaths annually, including >47,000 in the USA i

132 life-years (QALYs), number and percentage of overdose deaths averted, number of HIV-related deaths av

133 g opioids increase the risk of unintentional overdose deaths but also may increase mortality from car

134 From analysis of 661,565 overdose deaths from 1999 to 2017, we show that the age-

135 The increase in overdose deaths from prescription opioids and heroin in

136 ethanol), and post-mortem analyses of opioid overdose deaths have revealed an inverse correlation bet

137 crisis, with the third highest rate of drug overdose deaths in the United States.

138 d crisis with the third highest rate of drug overdose deaths in the US.

139 stem Mortality to evaluate trends in US drug overdose deaths involving opioids certified as unintenti

140 Opioid use disorder and overdose deaths is a public health crisis in the United

141 In the USA, an epidemic of opioid overdose deaths is occurring, many of which are from her

142 The overdose deaths occurred 9-10 months after the last nalt

143 During this time, opioid overdose deaths peaked at 59 deaths per 100 000 persons,

144 By December 2013, drug overdose deaths were down 17% (95% credible interval: -2

145 opioid epidemic has increased the number of overdose deaths with a concomitant increase in younger H

146 We also tracked HIV and HCV infections, overdose deaths, and jail population size.

147 ducing illicit opioid use, preventing opioid overdose deaths, and reducing the comorbidities and soci

148 surges in opioid-related addiction cases and overdose deaths.

149 s filled and the number of US opioid-related overdose deaths.

150 hanol may be a contributory factor in heroin overdose deaths.

151 neurotoxic and broadly cytotoxic, leading to overdose deaths.

152 ng to an alarming rise in medication-related overdose deaths.

153 ountries facing increasing numbers of opioid overdose deaths.

154 nyl, has led to an epidemic in addiction and overdose deaths.

155 rescribing reform substantially reduced drug overdose deaths.

156 No overdoses, deaths, or peripherally inserted central cath

157 tories in the year before an incident OUD or overdose diagnosis using a 2005-2016 commercial healthca

158 ion fills in the year before incident OUD or overdose diagnosis was prevalent, and the majority of th

159 prescription in the 12 months before OUD or overdose diagnosis, with the proportion significantly in

160 treatment-emergent adverse events including overdose did not differ between treatment groups.

161 study aimed to compare trends in use of drug overdose (DO) donors in adult vs. pediatric liver transp

162 rs was similar for recipients of anoxic drug overdose donor grafts and recipients of other grafts (li

163 Grafts from anoxic drug overdose donors were less frequently used compared with

164 ing the temporal and geographic variation in overdose emergencies may help guide public policy respon

165 Upon overdose, enhanced binding of insulin analog to Glut sup

166 The overdose epidemic emerged and increased in amplitude amo

167 ests that the increasing rates of the opioid overdose epidemic in Ohio were driven by the epidemic ho

168 Reversal of the drug overdose epidemic will be beneficial, but insufficient f

169 he authors review the scope of the abuse and overdose epidemic, prescription practices, and the asses

170 ze the spatiotemporal dynamics of the opioid overdose epidemic.

171 that of the decades-long HIV/AIDS and opioid-overdose epidemics but considerably smaller than that of

172 ined human immunodeficiency virus and opioid overdose epidemics.

173 al associations between georeferenced opioid overdose event (OOE) data from emergency medical service

174 r the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group

175 determine appropriateness of prescribing or overdose events.

176 clared a public health emergency, with fatal overdoses following relapse reaching epidemic proportion

177 ous acetylcysteine treatment for paracetamol overdose had circulating biomarkers measured at hospital

178 Serum samples of children with APAP overdose had significant elevation of miR-122-5p, miR-37

179 For years, research on APAP overdose has been focused on investigating the mechanism

180 itous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 r

181 The incidence of fatal overdoses has increased worldwide due to the widespread

182 Drug overdoses have become the number 1 cause of mortality in

183 lent in men, opioid relapse and fatal opioid overdoses have recently increased at a higher rate among

184 n analytical Markov model to simulate opioid overdose, HIV incidence, overdose-related deaths, and HI

185 dynamic functions of macrophages after APAP overdose, however, are not fully understood.

186 of vulnerability for the syndemic of opioid overdose, human immunodeficiency virus (HIV), and hepati

187 rmined-intent death from prescription opioid overdose, identified from the National Death Index.

188 e patients who died of a prescription opioid overdose in 2012 or 2013 were matched (up to 1:4) with 8

189 sic as well as quick diagnostics of possible overdose in emergency care.

190 Upon experimental APAP overdose in mice, monocyte-derived macrophages (MoMFs) m

191 ebo group, suicidal ideation and intentional overdose in one (1%) participant in the 30 mg/kg opicinu

192 ministration and dosing for suspected opioid overdose in out-of-hospital settings on mortality, rever

193 of otherwise healthy individuals due to drug overdose in the United States has major implications for

194 The rates of opioid overdose in the United States quadrupled between 1999 an

195 als aged 18 to 64 years with incident OUD or overdose in the United States.

196 meation of the intestine as well as enhancer overdosing in some areas due to non-uniform distribution

197 n-related emergency calls (n = 6,246) to map overdose incidents to 280 census block groups in Cincinn

198 e, practical emergence treatment for cocaine overdose includes administration of a benzodiazepine ant

199 r a large dose of naloxone upon detection of overdose-induced respiratory failure.

200 Unintentional overdose involving opioid analgesics is a leading cause

201 Acetaminophen (APAP) overdose is a frequent cause of drug-induced liver injur

202 Nonfatal opioid overdose is an opportunity to identify and treat substan

203 Opioid discontinuation after overdose is associated with lower risk for repeated over

204 ivation of beta-catenin signaling after APAP overdose is associated with timely liver regeneration.

205 Paracetamol overdose is common but patient stratification is subopti

206 48,000 attributed deaths in 2017, the opioid overdose is now the leading cause of death amongst Ameri

207 Acetaminophen (APAP) overdose is one of the leading causes of hepatotoxicity

208 The main cause of death from opioid overdose is respiratory depression due to the activation

209 The primary cause of death from opioid overdose is respiratory failure.

210 nother medication mode of minimizing risk of overdose is take-home naloxone.

211 Acetaminophen overdose is the leading cause of acute liver failure.

212 taminophen (N-acetyl-para-aminophenol; APAP) overdose is the most common cause of acute liver failure

213 tory death (DCD) donors who died from opioid overdose is unknown.

214 iver injury after any insult, including APAP overdose, is followed by compensatory liver regeneration

215 ealed that liver injury due to acetaminophen overdose led to a directional migration of neutrophils t

216 mortality (RR 2.56 [95% CI: 1.72-3.80]) and overdose mortality (8.10 [4.48-14.66]), and discharged p

217 fentanyl with consequent increases in opioid overdose mortality As injection replaced oral consumptio

218 to 2017, we show that the age-specific drug overdose mortality curve for each birth-year cohort rise

219 Opioid overdose mortality has been increasing in the United Sta

220 Because opioid overdose mortality is often associated with economic con

221 tween state medical cannabis laws and opioid overdose mortality reversed direction from -21% to +23%

222 of external data on (1) arrest, (2) narcotic overdose mortality, and (3) biomarker-based sensitivity

223 rates (CMRs) for all-cause and drug-related overdose mortality, and mortality rate ratios (MRRs) acc

224 rienced slower increases in opioid analgesic overdose mortality.

225 laws were associated with changes in opioid overdose mortality.

226 exerted large conflicting effects on opioid overdose mortality.

227 abolism, n = 2) and 34 with ALF (paracetamol overdose, n = 6; viral infections, n = 3; mushroom poiso

228 Five fatal overdoses occurred (two in the XR-NTX group and three in

229 outcomes of in-hospital postoperative opioid overdose (OD) and identify predictors of postoperative O

230 Overdose of acetaminophen (APAP) is the leading cause of

231 lgesic drug at recommended doses, whereas an overdose of APAP can cause severe liver damage.

232 strointestinal bleeding after an intentional overdose of concomitant sedatives and antidepressants) a

233 rge number of fatalities have been linked to overdose of fentanyl derivatives.

234 erexpression promotes resistance but a toxic overdose of signaling if the inhibitor is withdrawn.

235 detergent composition (liquid or powder) or overdosing of detergent did not significantly influence

236 Overdosing of obese women by 2016 AAO guidelines is not

237 tients who had taken intentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunte

238 d one AIDS), and four in the oral group (two overdoses, one pancreatic cancer, and one AIDS).

239 italizations, opioid prescriptions, and drug overdose (opioid or non-opioid).

240 areas and cell types mediating the cause of overdose- opioid-induced respiratory depression.

241 (1) a drug related adverse medical event or overdose or (2) a traumatic injury in the 30 days after

242 death of individuals with high-concentration overdose or compromised cardiac repolarization.

243 Serious outcomes after overdose or nonintentional exposures to medications used

244 scores (P < .001), and lower rates of opioid overdose (P = .04).

245 In a cohort of APAP overdose patients (N = 74) with and without established

246 oubled over the study period from 0.6 to 1.1 overdoses per 1000 cases.

247 n comorbidity index of 0 vs 2), diagnoses of overdose/poisoning (odds ratio, 1.35; 95% CI, 1.23-1.47)

248 onfatal, unintentional opioid-related opioid overdoses presenting to a US urban emergency department

249 s important for the development of effective overdose prevention measures.

250 The overdose process can be interrupted by the administratio

251 The ongoing epidemics of opioid overdose raises an urgent need for effective antiaddicti

252 In 2017, Ohio had the second highest overdose rates in the US, with the city of Cincinnati ex

253 ns with opioid use disorder, increase opioid overdose rates, reverse system-level gains in expanding

254 Opiate abuse and overdose reached epidemic levels in the United States.

255 Of the 449 acetaminophen overdoses receiving acetylcysteine, 100 were recruited t

256 Main outcomes were mortality, reversal of overdose, recurrence of overdose, and harms.

257 to simulate opioid overdose, HIV incidence, overdose-related deaths, and HIV-related deaths in peopl

258 Acetaminophen (APAP) overdose represents the most frequent cause of acute liv

259 erious adverse event of accidental ribavirin overdose requiring hospitalization for monitoring; this

260 m of prevention and treatment interventions, overdose reversal, public health surveillance, and resea

261 rtant advances in chemical interventions for overdose reversal, strategies for opioid use disorder (O

262 re prescribed opioids at doses that increase overdose risk and exceed daily recommendations.

263 liceridine, a small nonpeptide with improved overdose safety.

264 Cincinnati experiencing a 50% rise in opioid overdoses since 2015.

265 In overdose situations, targeted detoxification strategies

266 Secondary outcomes included time to repeated overdose stratified by daily dosage as a time-varying co

267 its, 2) overlap of expression data from APAP overdose studies, and 3) predicted affected biological p

268 trends in methamphetamine (METH) misuse and overdose suggest society is inadvertently overlooking a

269 mortality and key causes of death, including overdose, suicide, HIV, hepatitis C virus, and other inj

270 in mortality from specific causes (eg, drug overdoses, suicides, organ system diseases) among young

271 resolution, they can be effective as opioid overdose surveillance indicators for basic research and

272 igher odds of death from prescription opioid overdose than those who received opioids from VA only (o

273 timal dosage to ensure drug delivery without overdosing the tissue.

274 various strategies in a mouse model of APAP overdose, the authors demonstrate that platelets partici

275 , including the steps "Check for a suspected overdose" (threshold, 85%; point estimate [PE], 95.8%; 9

276 ctable plasma concentration exposing them to overdose, toxicity, underdosing, and treatment failure.

277 ical evidence of clinical potential for drug overdose treatment without a question mark on the timing

278 f melanoma, and when accounting for putative overdosing, trended toward an increase in the survival b

279 response to rising rates of opioid abuse and overdose, U.S. states enacted laws to restrict the presc

280 The literature on insulin overdose, usually from suicide attempts, can help guide

281 d by the rapid onset of its action in opioid overdose victims, was directly documented in humans for

282 While increases in overdoses, viral hepatitis, and endocarditis associated

283 years, the cumulative incidence of repeated overdose was 17% (95% CI, 14% to 20%) for patients recei

284 Nonfatal opioid overdose was identified using International Classificati

285 After dose adjustment, NOAC overdosing was associated with increased all-cause morta

286 Risk of acute care service use and overdose were high following buprenorphine discontinuati

287 red acetylcysteine treatment for paracetamol overdose were recruited (985 in the MAPP cohort; 202 in

288 ty and liver injury at early times post-APAP overdose were unaffected by syndecan-1, suggesting that

289 umber of deaths were one and zero, non-fatal overdoses were one and two, admissions to hospital were

290 , and naloxone, an antidote used in fentanyl overdose, were also examined.

291 n for dose reduction, 43.0% were potentially overdosed, which was associated with a higher risk of ma

292 ghlighting a potential for abuse and risk of overdose with DOTNs aerosolized in an e-cigarette system

293 Nontransport after reversal of overdose with naloxone seems to be associated with a low

294 nsport versus nontransport after reversal of overdose with naloxone.

295 to a health care facility after reversal of overdose with naloxone.

296 following single or staggered acetaminophen overdose with normal serum alanine transaminase (ALT) an

297 tial for biomarkers to stratify patients who overdose with paracetamol.

298 all, over two-thirds of patients with OUD or overdose with prescription opioids were prescribed a mea

299 ity, including deaths from causes other than overdose, with a modest absolute risk difference.

300 ntramuscular naloxone for reversal of opioid overdose, with no difference in adverse events.